albany, new york -- (SBWIRE) -- 02/07/2019 -- Von Willebrand Disease - Market Insight, Epidemiology and Market Forecast - 2027

06 Feb. 19

Majority of the patients diagnosed with vWD in the United States belonged to the age group of 5-13 years.

1. It has been postulated that although the autosomal inheritance pattern of the disease suggests an equal distribution of male and female patients, the disease is often diagnosed at a higher rate in females owing to female specific hemostatic challenges.
2. VWD can be classified into three main types based on the nature of deficiencies related to Von Willebrand Factor namely: VWD Type 1, VWD Type 2, VWD Type 3.
3. VWD Type 2 is further sub divided into- Type 2A, 2B, 2M and 2N. They can also be broadly divided into Acquired and Inherited Types. It was observed that among those patients with defined vWD, 84% represented Type-1 followed by 11% Type2 and 6% Type-3.

(Albany, US) DelveInsight launched a new report on Von Willebrand Disease - Market Insight, Epidemiology and Market Forecast - 2027

Request for sample pages

Key topics covered

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Von Willebrand Disease market.
2. Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand Disease market.
3. To understand the future market competition in the Von Willebrand Disease market.

"According to DelveInsight, total number of diagnosed prevalent population of Von Willebrand disease (vWD) was estimated at around 13,969 in the US in 2016. Among the EU5, UK had the highest diagnosed prevalent population of Von Willebrand Disease (vWD) with 10,627 cases, followed by the Germany in 2016."

Due to the underlying complexity in diagnosis of Von Willebrand disease (vWD), treatable pool is less and at present the available treatment for Von Willebrand disease mainly comprises of Non-Replacement therapy, Replacement Therapy (including recombinant VWF) and Adjunct/Supportive therapies. The use of approved along with the use of off label drugs shows a significant market revenue that belong to the above mentioned therapeutic classes.

Market analysis study carried out for the period of 2016-2027 shows that the Market size of Von Willebrand disease was about USD 379.67 Million in 2016 in 7MM. Market is dominated by the use of human plasma derived factor concentrates and vasopressin analogues for the treatment of Von Willebrand disease. Market will be driven primarily by the use of improved diagnostic tools, novel therapeutic options and increased social awareness for Von Willebrand disease among the patient population. There has been a positive impact on the market with the recent approval of recombinant Von Willebrand Factor (Vonvendi: Shire) in the US, due to their novel method of development.
Companies covered

1. OctaPharma
2. CSL Behring
3. Grifols Biologicals
4. Shire
5. LFB USA
And many others

Drugs covered

1. Vonvendi
2. Wilfactin
And many others

Table of contents

1. Key Insights
2. Von Willebrand Disease (vWD): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of vWD in 2016
2.2. Total Market Share (%) Distribution of vWD in 2027
3. Disease Background and Overview: von Willebrand Disease (vWD)
3.1. Introduction
3.2. Classification
3.3. Clinical Manifestations
3.4. Pathophysiology
3.5. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
5. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease
6. Country Wise-Epidemiology of von Willebrand Disease
6.1. United States
6.1.1. Total Diagnosed Prevalent Population of von Willebrand Disease in the US
6.1.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in the US
6.1.3. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the US
6.1.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in the US
6.2. EU5 Countries
6.3. Germany
6.3.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany
6.3.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
6.3.3. Type Specific Diagnosed Prevalence of von Willebrand Disease in Germany
6.3.4. Age Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany
6.4. France
6.4.1. Total Diagnosed Prevalent Population of Von Willebrand Disease in France
6.4.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in France
6.4.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in France
6.4.4. Age Specific Diagnosed Prevalent Population of Von Willebrand Disease in France
6.5. Italy
6.5.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Italy
6.5.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Italy
6.5.3. Type Specific Diagnosed Prevalence of von Willebrand Disease in Italy
6.5.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Italy
6.6. Spain
6.6.1. Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain
6.6.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
6.6.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain
6.6.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain
6.7. United Kingdom
6.7.1. Total Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
6.7.2. Sex-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom
6.7.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in the United Kingdom
6.7.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in United Kingdom
6.8. Japan
6.8.1. Total Diagnosed Prevalent Population of von Willebrand Disease in Japan
6.8.2. Sex-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Japan
6.8.3. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Japan
6.8.4. Age Specific Diagnosed Prevalent Population of von Willebrand Disease in Japan
7. Treatment Algorithm, Current Treatment, and Medical Practices
8. Unmet Needs
8.1. Marketed Drugs
8.2. VONVENDI: Shire
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Clinical Development
8.2.5. Advantages & Disadvantages
8.2.6. Safety and Efficacy
8.2.7. Product Profile
8.3. Voncento : CSL- Behring
8.3.1. Drug Description
8.3.2. Mechanism of Action
8.3.3. Regulatory Milestones
8.3.4. Advantages & Disadvantages
8.3.5. Safety and Efficacy
8.3.6. Product Profile
8.4. Humate P: CSL Behring
8.4.1. Drug Description
8.4.2. Mechanism of Action
8.4.3. Regulatory Milestones
8.4.4. Advantages & Disadvantages
8.4.5. Safety and Efficacy
8.4.6. Product Profile
8.5. WILATE : Octa Pharma
8.5.1. Drug Description
8.5.2. Mechanism of Action
8.5.3. Regulatory Milestones
8.5.4. Advantages & Disadvantages
8.5.5. Safety and Efficacy
8.5.6. Product Profile
8.6. Wilfactin: LFB
8.6.1. Drug Description
8.6.2. Mechanism of Action
8.6.3. Regulatory Milestones
8.6.4. Advantages & Disadvantages
8.6.5. Product Profile
8.7. Desmopressin: Ferring Pharmaceuticals
8.7.1. Drug Description
8.7.2. Mechanism of Action
8.7.3. Regulatory Milestones
8.7.4. Advantages & Disadvantages
8.7.5. Product Profile
8.8. ALPHANATE: Grifols Biological Inc
8.8.1. Drug Description
8.8.2. Mechanism of Action
8.8.3. Regulatory Milestones
8.8.4. Advantages & Disadvantages
8.8.5. Safety and Efficacy
8.8.6. Product Profile
8.9. Immunate: Shire
8.9.1. Drug Description
8.9.2. Mechanism of Action
8.9.3. Advantages & Disadvantages
8.9.4. Safety and Efficacy
8.9.5. Product Profile
8.10. Fanhdi: Grifols Biological Inc
8.10.1. Drug Description
8.10.2. Mechanism of Action
8.10.3. Regulatory Milestones
8.10.4. Advantages & Disadvantages
8.10.5. Safety and Efficacy
8.10.6. Product Profile
9. Von Willebrand Disease: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Von Willebrand Disease in 7MM
10. The United States Market Outlook
10.1. United States Market Size
10.1.1. Total Market size of Von Willebrand Disease
10.1.2. Market Size by Therapies
11. EU-5 Countries: Market Outlook
11.1. Germany
11.1.1. Total Market size of von Willebrand Disease in Germany
11.1.2. Market Size by Therapies
11.2. France
11.2.1. Total Market size of Von Willebrand Disease
11.2.2. Market Size by Therapies
11.3. Italy
11.3.1. Total Market size of Von Willebrand Disease
11.3.2. Market Size by Therapies
11.4. Spain
11.4.1. Total Market size of von Willebrand Disease
11.4.2. Market Size by Therapies
11.5. United Kingdom
11.5.1. Total Market size of Von Willebrand Disease
11.5.2. Market Size by Therapies
11.6. Japan: Market Outlook
11.6.1. Total Market size of von Willebrand Disease
12. Market Drivers
13. Market Barriers
14. Appendix
14.1. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight